Real-World study tests migraine prevention pill in UK clinics
NCT ID NCT07690215
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This study looks at how well atogepant, a daily pill, works to prevent migraines in adults treated in UK primary care. About 200 people with migraine will take atogepant as prescribed by their doctor and report their symptoms and healthcare use for up to 48 weeks. The goal is to see if atogepant improves their condition in real-world settings, outside of strict clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- atogepant
- What this could lead to
- If successful, this study could confirm that atogepant works well in everyday primary care settings, helping more people prevent migraines effectively.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by other factors. Atogepant may not work for everyone and can cause side effects like nausea or constipation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 200 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Mar 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Adult patients with (EM) or chronic migraine (CM), who are to be treated preventative with atogepant.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Physician-confirmed diagnosis of migraine, classified as either episodic or chronic. * Have at least 1-year history of migraine with or without aura consistent with a diagnosis according to the International Classification of Headache Disorders 3rd edition (ICHD-3), 2018. * Without prior exposure to atogepant who are being prescribed atogepant in primary care for the prophylaxis of migraine with at least 4 migraine days per month. * Decision to initiate atogepant was made by a prescribing general practitioner (GP) or appropriate primary care health care professional (HCP) within a primary care setting, prior to and independent of any decision to approach the patient regarding participation in the study. * Willing and able to comply with the requirements of the study, including being able to read and comprehend written English at a level sufficient to understand and complete study patient-reported outcomes (PROs). * Not on concomitant preventive medication for migraine or have been on a stable preventive medication for migraine for at least 3 months prior to enrolment. * Access to a suitable device (e.g., laptop, tablet, or smartphone) to complete PRO measures. Exclusion Criteria: * Previously exposed to atogepant as routine therapy before the study period or from clinical trials experience prior to entry. * Enrolled in any interventional studies that may include investigational compounds for migraine. * Initiated on atogepant in secondary care and subsequently maintained in primary care. * Initiated on atogepant in primary care following specialist input via an 'advice and guidance' pathway. * Contraindications to atogepant administration as per local labelling. * Pregnant or planning to be pregnant or women of childbearing potential not using contraception. * In the opinion of the prescribing GP or appropriate primary care HCP, the patient has a history or current evidence of any condition that might interfere with the patient's ability to comply with the study requirements.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Migraine are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could a migraine injection also heal caregiver burnout?
- Can a quick Head-Turn test reveal the hidden inner ear effects of vestibular migraine?
- Brain wave markers may reveal who benefits from mindfulness for migraine
- Could talk therapy ease the burden of migraine for veterans?
- Can music and imagery tame migraines without drugs?
- Can a mineral ease severe headaches faster than standard painkillers?